A Prospective Feasibility Trial to Challenge Patient–Derived Pancreatic Cancer Organoids in Predicting Treatment Response
Open accessThe DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
Real-time isolation, propagation, and pharmacotyping of patient-derived pancreatic cancer organoids (PDOs) may enable treatment response prediction and personalization of pancreatic cancer (PC) therapy. In our methodology, PDOs are isolated from 54 patients with suspected or confirmed PC in the framework of a prospective feasibility trial. The drug response of single agents is determined by a viability assay. Areas under the curves (AUC) are clustered for each drug, and a prediction score is developed for combined regimens. Pharmacotyping profiles are obtained from 28 PDOs (efficacy 63.6%) after a median of 53 days (range 21–126 days). PDOs exhibit heterogeneous responses to the standard-of-care drugs, and are classified into high, intermediate, or low responder categories. Our developed prediction model allows a successful response prediction in treatment-naïve patients with an accuracy of 91.1% for first-line and 80.0% for second-line regimens, respectively. The power of prediction declines in pretreated patients (accuracy 40.0%), particularly with more than one prior line of chemotherapy. Progression-free survival (PFS) is significantly longer in previously treatment-naïve patients receiving a predicted tumor sensitive compared to a predicted tumor resistant regimen (mPFS 141 vs. 46 days; p = 0.0048). In conclusion, generation and pharmacotyping of PDOs is feasible in clinical routine and may provide substantial benefit.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
Von Hoff, D. D., Ervin, T., Arena, F. P., Chiorean, E. G., Infante, J., Moore, M., Seay, T., Tjulandin, S. A., Ma, W. W., Saleh, M. N., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1304369 · Cited by 6,712 · cited 1×
“The current standard-of-care first-line regimen in the advanced setting is either gemcitabine/nab-paclitaxel [3] or FOLFIRINOX (5-fluorouracil, leucovorin, irinotecan, and oxaliplatin) [4], usually guided by patients’ performance status and age.”
Genomic analyses identify molecular subtypes of pancreatic cancer
Bailey, P., Chang, D. K., Nones, K., Johns, A. L., Patch, A.-M., Gingras, M.-C., Miller, D. K., Christ, A. N., Bruxner, T. J. C., Quinn, M. C., et al. (2016) · Nature · doi:10.1038/nature16965 · Cited by 3,621 · cited 1×
“As such, GATA6 expression allows a distinction between classical and basal ‐ like subtypes [27]—with the latter being associated with chemoresistance and poor prognosis [28–30], while a high Ki ‐ 67 proliferation index is considered to have a negative impact on disease ‐ free survival [31–33].”
Maintenance Olaparib for Germline BRCA -Mutated Metastatic Pancreatic Cancer
Golan, T., Hammel, P., Reni, M., Van Cutsem, E., Macarulla, T., Hall, M. J., Park, J.-O., Hochhauser, D., Arnold, D., Oh, D.-Y., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1903387 · Cited by 2,302 · cited 1×
“As best ‐ in ‐ class examples, PARP inhibitors targeting germline BRCA1 or BRCA2 mutations [45], TRK inhibitors for NTRK1, NTRK2 , or NTRK3 fusions [46], and immune checkpoint inhibitors for tumors with DNA mismatch repair (MMR) ‐ deficiency or high microsatellite instability (MSI ‐”
Moffitt, R. A., Marayati, R., Flate, E. L., Volmar, K. E., Loeza, S. G. H., Hoadley, K. A., Rashid, N. U., Williams, L. A., Eaton, S. C., Chung, A. H., et al. (2015) · Nature Genetics · doi:10.1038/ng.3398 · Cited by 2,194
Organoid models of human and mouse ductal pancreatic cancer
Boj, S. F., Hwang, C.-I., Baker, L. A., Chio, I. I. C., Engle, D. D., Corbo, V., Jager, M., Ponz-Sarvise, M., Tiriac, H., Spector, M. S., et al. (2015) · Cell · doi:10.1016/j.cell.2014.12.021 · Cited by 2,150
Patient-derived organoids model treatment response of metastatic gastrointestinal cancers
Vlachogiannis, G., Hedayat, S., Vatsiou, A., Jamin, Y., Fernández-Mateos, J., Khan, K., Lampis, A., Eason, K., Huntingford, I., Burke, R., et al. (2018) · Science · doi:10.1126/science.aao2774 · Cited by 2,096 · cited 1×
“PDO-derived gene signatures in PC were found to predict chemotherapy sensitivity [19], and in vitro drug responses correlated with clinical response in various patient examples in gastrointestinal cancers [20,21].”
Integrated genomic characterization of pancreatic ductal adenocarcinoma
Raphael, B. J., Hruban, R. H., Aguirre, A. J., Moffitt, R. A., Yeh, J. J., Stewart, C., Robertson, A. G., Cherniack, A. D., Gupta, M., Getz, G., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.07.007 · Cited by 2,019 · cited 2×
“Driver mutations in pancreatic cancer, such as KRAS , TP53 , CDKN2A , SMAD4 , and several more, are mostly not druggable, but generate an exceptional inter ‐ and intratumor heterogeneity [12,13], inducing a considerable variation in treatment response.”
Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion
Straussman, R., Morikawa, T., Shee, K., Barzily-Rokni, M., Qian, Z. R., Du, J., Davis, A., Mongare, M. M., Gould, J., Frederick, D. T., et al. (2012) · Nature · doi:10.1038/nature11183 · Cited by 1,771 · cited 1×
“This might be explained by chemoresistance mechanisms mediated by components of the tumor microenvironment [41,42] increasingly emerging after several lines of treatment that the organoid model fails to fully recapitulate.”
Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets
Witkiewicz, A. K., McMillan, E. A., Balaji, U., Baek, G., Lin, W.-C., Mansour, J., Mollaee, M., Wagner, K.-U., Koduru, P., Yopp, A., et al. (2015) · Nature Communications · doi:10.1038/ncomms7744 · Cited by 1,115 · cited 1×
“Driver mutations in pancreatic cancer, such as KRAS, TP53, CDKN2A, SMAD4, and several more, are mostly not druggable, but generate an exceptional inter- and intratumor heterogeneity [11,12], inducing a considerable variation in treatment response.”
Organoid Profiling Identifies Common Responders to Chemotherapy in Pancreatic Cancer
Tiriac, H., Belleau, P., Engle, D. D., Plenker, D., Deschênes, A., Somerville, T. D. D., Froeling, F. E. M., Burkhart, R. A., Denroche, R. E., Jang, G.-H., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0349 · Cited by 1,092 · cited 3×
“5-FU and oxaliplatin w re th least effe tive substances among th five tested (no viability reduction above 50% for 5-FU), while irinotecan induced cytotoxicity at higher dosages, in line with previous literature [19] (Figure 2C–E).”
Cited by
Thorel, L., Perréard, M., Florent, R., Divoux, J., Coffy, S., Vincent, A., Gaggioli, C., Guasch, G., Gidrol, X., Weiswald, L.-B., et al. (2024) · Experimental & Molecular Medicine · doi:10.1038/s12276-024-01272-5 · Cited by 236
Xiang, D., He, A., Zhou, R., Wang, Y., Xiao, X., Gong, T., Kang, W., Lin, X., Wang, X., Consortium11, P.-B. D., et al. (2024) · Theranostics · doi:10.7150/thno.96027 · Cited by 108
Johnson, P. A., Menegatti, S., Chambers, A. C., Alibhai, D., Collard, T. J., Williams, A. C., Bayley, H., & Perriman, A. W. (2023) · Biofabrication · doi:10.1088/1758-5090/ac999f · Cited by 16
Metadata
- Authors
- Beutel, A. K., Schütte, L., Scheible, J., Roger, E., Müller, M., Perkhofer, L., Kestler, A. M. T. U., Kraus, J. M., Kestler, H. A., Barth, T. F. E., Lemke, J., Kornmann, M., Ettrich, T. J., Gout, J., Seufferlein, T., & Kleger, A.
- Venue
- Cancers
- Publisher
- MDPI AG
- Published
- 2021-05-21
- Volume
- 13
- Issue
- 11
- Pages
- 2539
- ISSN
- 2072-6694 (ISSN-L)
- OpenAlex
- W3163569031
- Cited by
- 65
- References
- 15
- FWCI
- 3.10
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A Prospective Feasibility Trial to Challenge Patient–Derived Pancreatic Cancer Organoids in Predicting Treatment Response. https://app.cochat.ai/papers/10.3390/cancers13112539
- The paper
- Beutel, A. K., Schütte, L., Scheible, J., Roger, E., Müller, M., Perkhofer, L., Kestler, A. M. T. U., Kraus, J. M., Kestler, H. A., Barth, T. F. E., Lemke, J., Kornmann, M., Ettrich, T. J., Gout, J., Seufferlein, T., & Kleger, A. (2021). A Prospective Feasibility Trial to Challenge Patient–Derived Pancreatic Cancer Organoids in Predicting Treatment Response. Cancers. https://doi.org/10.3390/cancers13112539
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.